Japanese firm acquires US drugmaker after increasing offer
The deal sees Sumitomo acquiring ownership of cancer and uterine fibroid treatments | Myovant initially rejected low offer that “undervalued” the company.
Biotech escalates genetic analysis tech dispute
The complaint centres on profiling tech used in genetic analysis | Last year, 10x Genomics accused NanoString of infringing multiple patents related to spatial profiling.
UPDATED: ITC blocks Chinese imports of rice-derived rHSA products after ALJ review
Commission overturns one ALJ finding but affirms all others, agreeing that Wuhan Healthgen infringed Ventria's rice seed patent | Dispute concerns recombinant human proteins derived from genetically engineered rice.
Surgical device maker hit with $10m damages in stapler patent dispute
Lawsuit centred on methods for stapling tissue during surgery | Delaware federal jury found in favour of Rex Medical.
Gilead inks deal for cancer-beating antibody
Gilead will have an exclusive licence and will pay MacroGenics $60 million upfront | Deal includes tiered, double-digit royalties on worldwide net sales.
Biotech wins $16.5 million in drug royalties dispute
Arbitration panel awarded the sum to Acorda to cover past royalties and interest | Acorda can now source the multiple sclerosis drug elsewhere.
In conversation with...Beatriz San Martin, Arnold & Porter
The scientist-turned IP specialist chats to LSIPR about why she ‘loves’ the IP sector, her views on policy and funding in science and research, and the cases she’s most proud of.
Pharma company raises pressure with hypotension drug lawsuit
Nexus raises second complaint against same parties in a month | Ready-to-use drug that can raise the blood pressure of hypotension patients at issue.
Teva breached antitrust rules over Copaxone, says EU
European Commission says pharma firm blocked generics over blockbuster MS drug| Teva “engaged in abusive conduct” to “artificially prolong the exclusivity” of Copaxone | Teva could be found to have infringed Article 102 of TFEU.
French pharma firm inks deal with tech provider
The partnership aims to progress drug discovery and development | Tech platform accelerates trials and provides higher quality trial data.
